Dispatch Biotherapeutics

Dispatch Biotherapeutics is a cancer immunotherapy biotech developing its first-in-class Flare platform, which combines engineered immunotherapy with a tumor-specific virus to target solid tumors. It emerged from stealth in July 2025 with $216M in funding and was named to the 2025 Endpoints 11 list.